CARDIATEC

FOUNDED

2021

INVESTED

2022 (Pre-Seed)

FOUNDERS

Raphael Peralta (CEO)
Dr Namshik Han (CTO)
Thelma Zamblocki (COO)

INDUSTRY

Biotechnology

Combatting Cardiovascular Diseases Using Artificial Intelligence

CardiaTec was founded by ambitious individuals from the University of Cambridge motivated to change the drug target discovery landscape for cardiovascular diseases and reduce its burden on public health. 

CardiaTec is applying AI to analyse large-scale multi-omic data to generate the next generation of cardiovascular disease drug targets. The ultimate goal of CardiaTec is to leverage their systems biology approach to better understand complex biological mechanisms underpinning disease development to uncover novel therapeutic pathways and bring to market new treatments that will help to save patients' lives.

WHY WE INVESTED

Arrow down - open module

PRODUCTS & SERVICES

Arrow down - open module

ABOUT THE LAIDLAW SCHOLAR

Arrow down - open module

RELATED STORIES

CardiaTec team portrait. From left to right: Dr. Namshik Han (CTO), Raphael Peralta (CEO), Thelma Zablocki (COO).CardiaTec Biosciences Secures £1.4M to Combat Cardiovascular Diseases Using Artificial Intelligence

CardiaTec, an AI drug target discovery company specialising in cardiovascular disease, has secured a £1.4m pre-seed investment led by Laidlaw Scholars Ventures and APEX Ventures.

July 6, 2022